Rarudine 50 mg, 300 mg, 300 mg Tablet
PDF Leaflet Revision Date: 28 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally once daily, without regard to food.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; effective contraception required for women of childbearing age.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels.
- Metformin contraindicated.
- Avoid antacids containing polyvalent cations.
Contraindications
- Hypersensitivity to components
- Renal impairment < 80 mL/min
- Moderate to severe hepatic impairment
- Pregnancy and lactation
- Women of child-bearing age without effective contraception
Common side effects
- Nausea
- Diarrhoea
- Headache
- Rash
- Fatigue
Counselling Points
- Take once daily without food.
- Report any signs of liver problems.
- Use effective contraception if of childbearing age.
Serious warnings
- Risk of lactic acidosis and severe hepatomegaly.
- Monitor liver function in HBV co-infected patients.
- Immune Reconstitution Inflammatory Syndrome (IRIS) may occur.
Important Disclaimer
The Rarudine 50 mg, 300 mg, 300 mg Tablet professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
